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Summary Surgical resection remains the only proven
curative treatment for peri-hilar cholangiocarcinoma.
Despite recent advances in liver surgery techniques
and perioperative care, resection for peri-hilar cholan-
giocarcinoma remains associated with significant
morbidity and mortality. Considerable variation in
the perioperative management of these patients ex-
ists. Optimal perioperative management has the
potential to deliver improved outcomes. This article
seeks to summarize the evidence underpinning best
practice in the perioperative care of patients undergo-
ing resection of peri-hilar cholangiocarcinoma. The
authors also seek to identify areas where research
efforts and future clinical trials should be targeted.
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Introduction
Complete surgical resection represents the only cura-
tive option in peri-hilar cholangiocarcinoma (pCCA);
however, the disease is often silent in the early stages
and many patients have advanced disease at presen-
tation. The majority of patients undergoing resection
do not achieve long-term disease control, but radi-
cal curative resection can achieve a 5-year survival of
11 to 44% [1]. Surgical resection represents a major
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undertaking, with mortality in western specialist cen-
tres ranging from 13% [2] to 15% [3], and morbidity
of up to 40% [4]. Research to improve postoperative
outcomes through optimized perioperative manage-
ment is urgently needed to reduce this mortality and
morbidity burden and minimize management varia-
tion. This article seeks to summarize the evidence
underpinning best practice in the perioperative care
of patients undergoing resection of peri-hilar cholan-
giocarcinoma.
Cholangiocarcinoma
Cholangiocarcinoma represents a spectrum of biliary
tract adenocarcinomas. The disease encompasses in-
tra-hepatic (10%) and extra-hepatic cases, including
peri-hilar disease (50%) arising at or near the con-
fluence of the hepatic ducts, and distal disease (40%;
[5]).
Patients with surgically resectable disease enjoy the
most favourable prognosis, and this is a key determi-
nate in the staging of pCCA [6]. The most commonly
used staging system is the Union for International
Cancer Control/American Joint Committee on Can-
cer (UICC/AJCC) 2010 revision of the tumour, node,
metastasis (TNM) classification, separating cholan-
giocarcinoma into intra-hepatic, hilar and distal dis-
ease, respectively [7, p. 201].
None of the staging systems accurately predict sur-
vival. The most important staging and predictive issue
is surgical resectability. The AJCC system is based on
pathological outcome following resection.
Clinical preoperative staging systems for pCCA
include the Bismuth–Corlette and Memorial Sloan
Kettering Cancer Centre (MSKCC) systems. Bis-
muth–Corlette classifies patients on the extent of
biliary involvement but does not incorporate vascu-
lar involvement or lobar atrophy. As such, it cannot
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be used for predicting resectability. MSKCC builds
on Bismuth–Corlette and includes longitudinal and
radial extension of the tumour to more accurately
predict resectability. T staging includes local tumour
involvement, portal vein involvement and hepatic lo-
bar atrophy. This staging system has been externally
validated and accurately predicts resectability, proba-
bility of metastatic disease and long-term survival in
the preoperative setting [6].
Resectability is ultimately determined at the time of
surgery, as these tumours often extend into the liver
and major vascular structures, with accurate preop-
erative evaluation of these areas difficult. Therefore,
surgical exploration with or without trial dissection
is appropriate for potentially resectable disease based
on preoperative imaging [8].
For pCCA, bile duct resection alone results in high
local recurrence rates [9]. The addition of hepatic re-
section improves R0 resection rate [10]. R0 resection
is the best management option for prolonged survival,
where technically feasible [11].
Neoadjuvant therapy and liver transplantation are
not considered standard of care at the current time.
The Mayo Clinic considers liver transplantation in
highly selected cases of early-stage local unresectable
peri-hilar CCA in patients who have completed thor-
ough staging, assessment and neoadjuvant chemora-
diotherapy [12].
The published Mayo experience found a statis-
tically significant improved survival following their
transplantation protocol with 92% 1-year, 82% 3-year
and 82% 5-year survival. This compared to 82%,
48% and 21%, respectively, following resection only
[13]. The ongoing French Phase III Transphil trial
compares preoperative capecitabine and radiother-
apy followed by liver transplantation with standard
surgical resection (NCT 02232932).
Biliary drainage
Jaundice is often the first presenting symptom of
pCCA, and whether preoperative biliary decompres-
sion should be performed remains controversial [14].
Ribero D et al., found that preoperative cholangitis
and insufficient functional residual liver volume are
the major determinants of hepatic insufficiency and
liver failure-related death. Given the association be-
tween biliary drainage and cholangitis, they advocate
that the preoperative approach to patients with peri-
hilar CCA should be optimized to minimize the risk of
cholangitis [15].
A number of recent meta-analyses have focused on
this issue. Moole H et al. found that patients with ma-
lignant biliary jaundice requiring surgery who under-
went biliary decompression had significantly less ma-
jor adverse effects those who went directly to surgery.
However, this study included all malignant causes of
biliary obstruction [16].
The optimal method (endoscopic versus percuta-
neous transhepatic) by which to perform preopera-
tive biliary drainage is debated. The Dutch multicen-
tre DRAINAGE trial was designed to identify a differ-
ence in the number of severe drainage-related compli-
cations between endoscopic and percutaneous tran-
shepatic approaches in patients with pCCA selected to
undergo major liver resection. The trial hypothesized
that less complications would occur in the percuta-
neous group. This trial identified an increased mor-
bidity risk in the percutaneous group and was subse-
quently prematurely terminated [17].
This issue remains debatable and patients are man-
aged according to local unit protocols. Randomized
trials are needed to identify those who will benefit
most from biliary drainage, and the optimal method
for biliary drainage. In the presence of jaundice in
perihilar cholangiocarcinoma patients planned for
surgery, the authors recommend preoperative biliary
decompression of the planned future liver remnant by
the endoscopic method. Metallic stents offer higher
patency duration than plastic stents [18].
Optimizing the future liver remnant
Postoperative hepatic failure (PHF) is a leading cause
of death following liver surgery [19]. Optimizing the
future liver remnant is key to maintaining adequate
liver function postoperatively and minimizing the risk
of PHF. Standard principles of liver resection should
be maintained, including minimized blood loss, hy-
potension and the judicious use of hepatic inflow oc-
clusion. Jaundice impairs regeneration by impedance
of portal blood flow. Hepatic resection exacerbates
this decrease in portal flow and hence regeneration.
Although preoperative biliary drainage is controver-
sial, as described previously, adequate drainage of the
future liver remnant is deemed a necessity if it is to
be a small liver remnant [20]. If the liver volume is
below threshold, then regeneration ceases, as other
metabolic functions assume priority [21]. A contin-
ued imbalance will lead to liver failure. These issues
are of overriding importance in peri-hilar resection,
where extended resection and caudate lobectomy may
be indicated [22].
If the future liver remnant is deemed inadequate
on preoperative assessment, then portal venous em-
bolization (PVE) can be considered. Occlusion of por-
tal vein branches to liver that is to be resected can
induce lobar hypertrophy in the future liver remnant.
This is assessed by CT volumetric analysis. Portal ve-
nous embolization can increase the remnant volume
with low morbidity [23]. Thus, PVE has a potential
benefit for patients with advanced biliary cancer who
are to undergo extended, complex hepatectomy [24].
There are a number of non-randomised studies; there
are, however, no randomized data currently available
for this intervention.
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Table 1 Pre-operative risk score to predict unresectable
peri-hilar cholangiocarcinoma at staging laparoscopy
Variable Classes Points
Tumour size <4.5cm 0
>4.5cm 1
Portal vein involvement None or unilateral 0
Bilateral or main stem 1
Suspected LN metastases None or N1 0
N2 1
Suspected extra-hepatic metastases No 0
Yes 2
Table 2 Predicted and observed risks according to risk
score
Group Total points Unresectability at staging La-
paroscopy
Predicted (%) Observed (%)
Low risk 0 7.2 6.4
Intermediate risk 1 21.3 28.2





A recent case–control analysis of the potential role
of ALPPS (associating liver partition and portal vein
ligation for staged hepatectomy) for extended hepa-
tectomy in pCCA resection by Olthof PB et al. found
inferior outcomes in ALPPS-treated patients com-
pared to standard extended hepatectomy approaches.
ALPPS is therefore not currently recommended for
pCCA, and as such, portal vein embolization remains
the method of choice for increasing the functional
liver remnant [25].
Staging laparoscopy
Staging laparoscopy is used in the staging of peri-hi-
lar cholangiocarcinoma following radiological assess-
ment to determine the presence or absence of radio-
logically occult metastases, thereby reducing the inci-
dence of unnecessary laparotomy [26].
Bird et al. suggested that staging laparoscopy has
a 27% all-cause yield of unresectable disease and
a sensitivity of 71% for peritoneal disease [27]. How-
ever, there remains debate regarding the value of
routine staging laparoscopy. Coelen et al. addressed
this issue in a pooled meta-analysis of 12 studies
published in 2016, suggesting that 25% of patients
with potentially resectable pCCA benefit from staging
laparoscopy with the highest sensitivity for peritoneal
metastases [28]. They suggest that with further im-
provement of radiological techniques through time, it
may be possible to identify patients who will benefit
most from laparoscopy. Until such time, the au-
thors recommend staging laparoscopy for exclusion
of peritoneal metastases.
Coelen et al. proposed a preoperative risk score
for selection into laparoscopy that demonstrated good
discrimination in predicting unresectability, stratify-
ing patients into low, intermediate and high risk (Ta-
bles 1 and 2). This scoring system has not been exter-
nally validated but may help identify those patients in
whom staging laparoscopy offers most benefit [29].
Nutrition
Nutritional deficiencies in patients presenting with
pCCA pose a significant risk to perioperative out-
comes. The evidence base is poor due to the relative
scarcity of the disease, and as a result, the manage-
ment strategy must be extrapolated from other biliary
tract cancers including pancreatic cancer.
Obstruction of biliary flow leads to jaundice (the
most common presenting symptom) with malabsorp-
tion and maldigestion through impaired lipid emul-
sification [30]. Furthermore, there is the additional
nutritional compromise due to biliary sepsis. The im-
pact of biliary stenting on preoperative nutritional op-
timization has not been documented in cholangiocar-
cinoma.
The international consensus definition of cancer
cachexia includes weight loss (main criterion), low
muscle mass (sarcopenia) and low body mass index,
and is associated with increased mortality risk. Af-
fecting up to 80% of pancreatic cancer patients, the
syndrome of cancer cachexia can also include many
more pathophysiological drivers such as inflamma-
tion, altered protein metabolism, skeletal muscle loss,
adipose tissue loss, anorexia, malabsorption and neu-
rohormonal changes [31].
Sarcopenia is associated with poor prognosis in
liver surgery for colorectal metastases [32]. More
recently, it has been demonstrated to increase the
rate of liver failure in patients undergoing major hep-
atectomy with extra-hepatic bile duct resection for
pCCA [33]. In resection of intrahepatic cholangio-
carcinoma, sarcopenia is also associated with higher
postoperative mortality [34].
Causation of nutritional deficiency may vary in
pCCA. Screening for causation and tailored pre- and
postoperative management is essential. There have
been no studies examining nutritional intervention
in patients presenting with resectable pCCA and this
should form a focus of urgent further research.
Preoperative fitness assessment
The substantial physiological insult of major hepatec-
tomy, alone or in conjunction with bile duct resection,
is associated with high rates of postoperative morbid-
ity. Identification of those patients at risk of devel-
oping significant postoperative morbidity plays a key
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role in the assessment of patients prior to pCCA re-
section.
Cardiopulmonary exercise testing (CPET) is an ob-
jective method of assessing preoperative cardiopul-
monary fitness, with the aim of improving accuracy
of preoperative prediction of postoperative complica-
tions and mortality. The role of CPET in liver surgery
has been examined. In 104 high-risk patients under-
going hepatectomy, oxygen uptake at the anaerobic or
lactate threshold (AT) was the only CPET predictor of
postoperative morbidity on multivariate analysis [35].
Another study suggested that patients with higher AT
have earlier hospital discharge, but that a low relative
oxygen uptake at the AT did not confer a significantly
higher risk of postoperative complications. This retro-
spective study suggested that the utilization of CPET
to tailor perioperative care had minimized the impact
of lower fitness, consequently suggesting that CPET-
assessed poor fitness should not be deemed a bar-
rier to surgical intervention in elective hepatectomy.
CPET assessment should therefore be interpreted in
the context of a wider anaesthetic review and should
aid complex perioperative decision-making [36].
CPET assessment is not universally used in the
preoperative assessment of pCCA. Further studies are
needed to examine the role of CPET and the values
of most importance when predicting the outcome of
pCCA patients undergoing resection.
Prehabilitation
Prehabilitation aims to prevent or minimize the mor-
bidity of surgery [37]. These preoperative interven-
tions focus on preoperative fitness, nutrition, educa-
tion and preoperative psychological status [38]. In
liver surgery, a CT identified that a 4-week program
of exercise was capable of delivering meaningful im-
provements in preoperative fitness in patients prior to
hepatectomy for colorectal liver metastasis [39].
There are no studies assessing prehabilitation in
pCCA. The feasibility of prehabilitation in patients
presenting with cholangiocarcinoma needs further
investigation to establish whether it could be used to
mitigate the high perioperative mortality and mor-
bidity.
Enhanced recovery
Enhanced recovery after surgery (ERAS) has been
shown to improve perioperative outcomes and reduce
cost in colorectal surgery, where it is now deemed
a standard of care [40]. It is not yet standard of care
in liver surgery but can be successfully implemented
without compromising morbidity or mortality rates
[41]. Many of the principles are derived from colorec-
tal surgery, but distinct differences exist which may
impede implementation in hepatopancreatobiliary
(HPB) surgery [42]. ERAS aims to decrease variabil-
ity in postoperative management, enhance quality of
care and improve outcomes including length of in-
patient hospital stay. ERAS protocols include greater
preoperative education, preoperative oral carbohy-
drate loading, postoperative goal-directed therapy,
early mobilization and physiotherapy.
There are several studies focused on ERAS in liver
surgery. In 2013, Jones C et al. conducted a ran-
domised controlled trial (RCT) of enhanced recov-
ery versus standard care in open resection and found
ERAS protocols safe and effective, with faster recov-
ery and discharge in the ERAS cohort. They also re-
ported fewer medical-related complications and im-
proved quality of life in the ERAS-treated group [43].
Savikko J et al. safely implemented a liver ERAS pro-
tocol with discharge within 4 days and without any
significant increase in adverse events in a primarily
open-resected cohort published in 2015 [44]. The
largest series of ERAS in liver surgery included 303 pa-
tients undergoing colorectal livermetastasis resection.
This study suggested that ERAS can be universally ap-
plied, and that the benefits accrue with time [45]. It
was suggested that ERAS should be considered stan-
dard of care in hepatectomy for CRLM.
Overall evidence from systematic reviews is lim-
ited, retrospective in nature and largely focused on
open resections. However, they all share similar con-
clusions that ERAS is a safe and effective program
in liver surgery. Ahmed EA et al. found that fast-
track enhanced recovery programs were safe and fea-
sible, and recommend further work on multimodal
analgesia and overall adherence to the programs [46].
The meta-analysis by Zhao Y et al. included 7 RCTs
and further divided the analysis into laparoscopic and
open subgroups to explore the effectiveness of ERAS
in these different surgical approaches. Again, ERAS
programs can enhance short-term recovery after liver
resection in both approaches and are safe and worth-
while. Protocol-specific ERAS guidelines for liver re-
section are recommended [47].
Peri-hilar cholangiocarcinoma is often excluded
from series describing ERAS in liver surgery. No
study has specifically addressed ERAS in the con-
text of pCCA resection. A recent publication by Yip
et al. included 27 patients with pCCA in a series of
223 patients undergoing hepatectomy [48]. Whilst this
demonstrates feasibility, tailoring of ERAS programs
for pCCA is urgently needed.
There are concerns specific to cholangiocarcinoma,
primarily anastomotic leak and collections secondary
to the formation of biliary-enteric anastomoses. As
such, this procedure is associated with greater mor-
bidity than standard liver resection. Future studies in
pCCA should focus on these issues.
In view of the complications associated with peri-
hilar resection, we routinely follow-up all postopera-
tive patients within 2 weeks of resection. In addition,
all patients have access to a hepatobiliary specialist
nurse-led telephone clinic.
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Chemotherapy
Most patients undergoing resection for pCCA will de-
velop recurrence. Predictors of recurrence include
positive margin status, vascular invasion and lymph
node metastasis [7, p. 219].
The European Society of Medical Oncology and
the National Comprehensive Cancer Network suggest
chemotherapy for both margin-negative and margin-
positive resected patients [49]. On the basis of im-
proved survival in periampullary cancer in the ESPAC-
3 trial, gemcitabine or fluorouracil have been consid-
ered acceptable adjuvant chemotherapy for pCCA
[50].
The recently reported UK BilCap Phase III trial
found much extended median survival with capecita-
bine. In 430 patients, capecitabine was associated
with a 25% lower risk of death compared to observa-
tion alone [51]. Per protocol analysis demonstrated
a statistically significant survival benefit. This in-
cluded large numbers of R1 resections but is deemed
clinically highly relevant. This would suggest adjuvant
capecitabine to be considered the new standard of
care in biliary tract cancer [52].
Preoperative chemotherapy or radiotherapy is not
considered routine treatment, in part due to the com-
plications of jaundice and malnutrition. However, in
selected patients there may be benefit. A small study
identified complete pathological response and mar-
gin-negative resection in 3 out of 9 patients with extra-
hepatic CCA [53]. Further work identified a survival
benefit despite the neo-adjuvant cohort having more
advanced disease [54]. These promising early find-
ings warrant further investigation with appropriately
powered clinical trials.
No prospective clinical trials have identified a ben-
efit with adjuvant radiotherapy.
Conclusions
Despite improvements in overall survival and ad-
vances in liver surgery, morbidity and mortality rates
remain high in patients undergoing resection for peri-
hilar cholangiocarcinoma.
The incidence of nutritional compromise in pCCA
is unknown but likely to be high; nutritional optimiza-
tion is likely to confer a benefit on postoperative out-
comes. There are no primary studies assessing preha-
bilitation in pCCA. The feasibility of prehabilitation in
patients presenting with pCCA needs investigation.
In the presence of jaundice, biliary drainage to opti-
mize the future liver remnant and prevent cholangitis
is essential. Where the functional liver remnant (FLR)
will be inadequate, PVE remains the method of choice
to increase remnant volume.
Staging laparoscopy is highly sensitive for the de-
tection of radiologically occult metastases and should
therefore be considered standard of care.
CPET assessment is not universally used in the pre-
operative cardiovascular fitness assessment of pCCA.
The role of CPET in predicting outcome needs further
assessment.
ERAS is not yet the standard of care in liver surgery
but can be successfully and safely implemented with-
out compromising morbidity or mortality rates. An
assessment of the ERAS specific to pCCA resection fo-
cusing on the appropriate components is warranted.
The majority of patients undergoing resection for
pCCA will develop recurrence. In light of the BilCap
trial, the authors recommend capecitabine as the new
standard of care for adjuvant chemotherapy.
There remains room for significant improvement
in the perioperative management of pCCA. Optimized
evidence-based perioperative management strategies
represent a target to improve outcome in these pa-
tients.
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